Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights in... BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. Mehr anzeigen
BioAge Labs, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025...
BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - BIOA PR Newswire NEW YORK, Jan. 13, 2025 NEW YORK, Jan...
Class Action Filed Against BioAge Labs, Inc. (BIOA) - March 10, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Jan. 9, 2025 NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The...
BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class...
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related...
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share...
RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash...
RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.04 | 0.8 | 5 | 5.19 | 4.4 | 395849 | 4.81807028 | CS |
| 4 | -0.06 | -1.17647058824 | 5.1 | 7.15 | 4.4 | 714899 | 5.73074885 | CS |
| 12 | -19.22 | -79.2250618302 | 24.26 | 25.33 | 3.85 | 780167 | 7.62056957 | CS |
| 26 | -17.46 | -77.6 | 22.5 | 26.62 | 3.85 | 709635 | 10.39931734 | CS |
| 52 | -17.46 | -77.6 | 22.5 | 26.62 | 3.85 | 709635 | 10.39931734 | CS |
| 156 | -17.46 | -77.6 | 22.5 | 26.62 | 3.85 | 709635 | 10.39931734 | CS |
| 260 | -17.46 | -77.6 | 22.5 | 26.62 | 3.85 | 709635 | 10.39931734 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
